Evidence supporting the use of: Alpha lipoic acid
For the health condition: Strokes

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Alpha lipoic acid (ALA) has been investigated for its potential neuroprotective effects in the context of stroke, primarily due to its antioxidant properties. Preclinical studies in animal models of ischemic stroke suggest that ALA can reduce oxidative stress, inhibit neuronal cell death, and improve functional recovery. For example, some rodent studies have demonstrated that administration of ALA after induced cerebral ischemia can decrease infarct size and improve neurological outcomes, likely by scavenging free radicals and enhancing endogenous antioxidant defenses (such as glutathione regeneration). Additionally, ALA may modulate inflammatory responses and improve mitochondrial function, which are relevant to secondary injury processes following stroke. However, clinical evidence in humans is limited. A few small trials and observational studies have examined ALA in the context of diabetic neuropathy or other neurological conditions, but well-controlled, large-scale clinical trials specifically evaluating ALA’s efficacy in acute stroke patients are lacking. Some pilot studies have suggested possible benefits when ALA is combined with other therapies (such as in combination with vitamin E or C), but the results are preliminary and not yet definitive. In summary, while there is a scientific rationale and some preclinical evidence supporting the use of alpha lipoic acid for stroke, robust clinical validation is currently insufficient. Therefore, ALA should not replace established stroke treatments, and its use in this context should be considered experimental pending further research.

More about alpha lipoic acid
More about Strokes